Compare Sirius XM Holdings Inc (SIRI) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sirius XM Holdings Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Sirius XM Holdings Inc trades at $26.42 (market cap $8.94B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Sirius XM Holdings Inc is the larger of the two by market cap, and Sirius XM Holdings Inc pays a 4.07% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sirius XM Holdings Inc for 103 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SIRI | TVTX | |
|---|---|---|
Market Cap | $8.94B | $5.02B |
Volume | 2,400,454 | 2,060,842 |
Sector | Media | Health |
52-Week High | $32.59 | $67.52 |
52-Week Low | $19.92 | $26.79 |
Typical Hold Time | 103 Days | 0 Days |
Enterprise Value | $18.22B | $5.15B |
Dividend Yield | 4.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sirius XM (SIRI) trades at $26.57, down slightly by 0.15% today, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net income margin of 10.23% for 2025, with revenue of $8.56B, and maintains a dividend payout. Recent news highlights a 53% YTD stock surge and positive analyst upgrades driven by advertising growth and a strategic YouTube partnership.
The outlook is cautiously optimistic, supported by strong analyst buy ratings (62.5%) and a consensus price target of $34.43, implying significant upside. Key risks include recent earnings misses, high debt levels, and competitive pressures in the media sector. Cash flow trends show improvement, with net cash flow turning positive in 2026 projections.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
